Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
Primary Purpose
Infection; Viral, Enterovirus
Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Inactivated Enterovirus Type 71 Vaccine
Placebo
Sponsored by

About this trial
This is an interventional prevention trial for Infection; Viral, Enterovirus
Eligibility Criteria
Inclusion Criteria:
- Healthy males and females, aged from 18 to 49 years old. Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
- Provided legal identification for the sake of recruitment.
- Subjects are able to understand and sign informed consents.
Exclusion Criteria:
- Histroy of Hand-foot-mouth Disease
- Women of lactation, pregnancy or about to be pregnant in 60 days
- Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
- Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
- Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
- Epilepsy, seizures or convulsions history, or family history of mental illness
- Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
- History of asthma, angioedema, diabetes or malignancy
- History of thyroidectomy or thyroid disease that required medication within the past 12 months
- Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
- Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
- Acute illness or acute exacerbation of chronic disease within the past 7 days
- Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
- History of any blood products within 3 months
- Administration of any live attenuated vaccine within 28 days
- Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
- Axillary temperature > 37.0 centigrade before vaccination
- Abnormal laboratory parameters before vaccination
- Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Sites / Locations
- GuangXi Center for Diseases Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Placebo Comparator
Placebo Comparator
Arm Label
Group 1: 200U EV71 vaccine
Group 2: 400U EV71 vaccine
Group 1: Placebo
Group 2: Placebo
Arm Description
12 adults received 3 doses of 200U EV71 vaccine 14 days apart
12 adults received 3 doses of 400U EV71 vaccine 14 days apart
6 adults received 3 doses of placebo 14 days apart
6 adults received 3 doses of placebo 14 days apart
Outcomes
Primary Outcome Measures
To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses
Secondary Outcome Measures
Full Information
NCT ID
NCT01273233
First Posted
January 7, 2011
Last Updated
March 13, 2013
Sponsor
Sinovac Biotech Co., Ltd
1. Study Identification
Unique Protocol Identification Number
NCT01273233
Brief Title
Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
Official Title
A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
Study Type
Interventional
2. Study Status
Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
February 2011 (Actual)
Study Completion Date
February 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A blind, randomized and placebo-controlled clinical trial with Inactivated Enterovirus Type 71 Vaccines in healthy adults
Detailed Description
A total of 36 eligible subjects aged from 18 to 49 years will be enrolled in the study, they will be randomized to receive two different dosage of vaccine candidate or placebo to evaluate the safety of this vaccine in adults
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection; Viral, Enterovirus
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1: 200U EV71 vaccine
Arm Type
Experimental
Arm Description
12 adults received 3 doses of 200U EV71 vaccine 14 days apart
Arm Title
Group 2: 400U EV71 vaccine
Arm Type
Experimental
Arm Description
12 adults received 3 doses of 400U EV71 vaccine 14 days apart
Arm Title
Group 1: Placebo
Arm Type
Placebo Comparator
Arm Description
6 adults received 3 doses of placebo 14 days apart
Arm Title
Group 2: Placebo
Arm Type
Placebo Comparator
Arm Description
6 adults received 3 doses of placebo 14 days apart
Intervention Type
Biological
Intervention Name(s)
Inactivated Enterovirus Type 71 Vaccine
Other Intervention Name(s)
EV71 Vaccine
Intervention Description
A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
EV71 Vaccine
Intervention Description
Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Primary Outcome Measure Information:
Title
To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy males and females, aged from 18 to 49 years old. Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
Provided legal identification for the sake of recruitment.
Subjects are able to understand and sign informed consents.
Exclusion Criteria:
Histroy of Hand-foot-mouth Disease
Women of lactation, pregnancy or about to be pregnant in 60 days
Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
Epilepsy, seizures or convulsions history, or family history of mental illness
Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
History of asthma, angioedema, diabetes or malignancy
History of thyroidectomy or thyroid disease that required medication within the past 12 months
Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
Acute illness or acute exacerbation of chronic disease within the past 7 days
Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
History of any blood products within 3 months
Administration of any live attenuated vaccine within 28 days
Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
Axillary temperature > 37.0 centigrade before vaccination
Abnormal laboratory parameters before vaccination
Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yan-ping Li, MD
Organizational Affiliation
Guangxi Centers for Disease Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
GuangXi Center for Diseases Control and Prevention
City
Nanning
State/Province
Guangxi
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
22426327
Citation
Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012 May 9;30(22):3295-303. doi: 10.1016/j.vaccine.2012.03.010. Epub 2012 Mar 15.
Results Reference
derived
Learn more about this trial
Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
We'll reach out to this number within 24 hrs